Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Torasemide | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Torasemide | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Torasemide | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Torasemide | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Torasemide | hsa00830 | Retinol metabolism | 2.20E-02 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | Torasemide | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Torasemide | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Torasemide | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Torasemide | hsa04064 | NF-kappa B signaling pathway | 9.70E-03 | 12 | O00463, P14778, P01584, P01375, Q04759, Q13077, Q16548, P06239, Q8WV28, P24522, P09341, Q9NQC7 | TRAF5, IL1R1, IL1B, TNF, PRKCQ, TRAF1, BCL2A1, LCK, BLNK, GADD45A, CXCL1, CYLD | More | | Torasemide | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | | Torasemide | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | Torasemide | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | Torasemide | hsa04380 | Osteoclast differentiation | 2.05E-03 | 12 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, SIRPA | More | | Torasemide | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | Torasemide | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | Torasemide | hsa04613 | Neutrophil extracellular trap formation | 1.86E-02 | 14 | O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P0C0S5, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AFZ, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | Torasemide | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | | Torasemide | hsa04625 | C-type lectin receptor signaling pathway | 8.11E-03 | 9 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | Torasemide | hsa04640 | Hematopoietic cell lineage | 4.31E-02 | 10 | P13612, P14778, P27930, P15144, P11836, P09693, P01732, P13765, P01375, P01584 | ITGA4, IL1R1, IL1R2, ANPEP, MS4A1, CD3G, CD8A, HLA-DOB, TNF, IL1B | More | | Torasemide | hsa04650 | Natural killer cell mediated cytotoxicity | 3.07E-04 | 11 | P01375, P78314, P06239, O60880, P20963, Q13241, P26718, O75015, P26717, Q14953, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | | Torasemide | hsa04657 | IL-17 signaling pathway | 1.92E-03 | 9 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375, P01584 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF, IL1B | More | | Torasemide | hsa04658 | Th1 and Th2 cell differentiation | 1.26E-02 | 10 | Q04759, P20963, P09693, Q16539, P06239, Q14765, P23771, Q9UL17, P13765, P23458 | PRKCQ, CD247, CD3G, MAPK14, LCK, STAT4, GATA3, TBX21, HLA-DOB, JAK1 | More | | Torasemide | hsa04659 | Th17 cell differentiation | 1.39E-02 | 11 | Q04759, Q16539, P06239, P13765, P14778, Q9UL17, P23771, P01584, P09693, P20963, P23458 | PRKCQ, MAPK14, LCK, HLA-DOB, IL1R1, TBX21, GATA3, IL1B, CD3G, CD247, JAK1 | More | | Torasemide | hsa04660 | T cell receptor signaling pathway | 1.11E-02 | 11 | P01375, Q04759, O95267, Q08881, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Torasemide | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | Torasemide | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.17E-02 | 8 | P14778, P01584, P51828, P22694, Q16539, Q14643, Q04759, P0DP24 | IL1R1, IL1B, ADCY7, PRKACB, MAPK14, ITPR1, PRKCQ, CALM2 | More | | Torasemide | hsa04912 | GnRH signaling pathway | 4.33E-02 | 6 | P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P22694 | ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, PRKACB | More | | Torasemide | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Torasemide | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | Torasemide | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | Torasemide | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | Torasemide | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Torasemide | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | | Torasemide | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | Torasemide | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | Torasemide | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | Torasemide | hsa05140 | Leishmaniasis | 2.29E-02 | 9 | P13612, O75015, P23458, P13765, O60603, P01375, P01584, Q16539, Q15080 | ITGA4, FCGR3B, JAK1, HLA-DOB, TLR2, TNF, IL1B, MAPK14, NCF4 | More | | Torasemide | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | | Torasemide | hsa05144 | Malaria | 2.43E-04 | 8 | P60033, P69905, P68871, O60603, P01375, P35443, P01584, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Torasemide | hsa05146 | Amoebiasis | 4.22E-03 | 11 | P01584, P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694, P08311 | IL1B, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, CTSG | More | | Torasemide | hsa05202 | Transcriptional misregulation in cancer | 6.59E-03 | 15 | P17844, P14780, P27930, Q16548, Q13077, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | DDX5, MMP9, IL1R2, BCL2A1, TRAF1, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Torasemide | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Torasemide | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | Torasemide | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.10E-02 | 8 | O95267, P20963, P09693, P06239, P23458, O60603, Q04759, Q16539 | RASGRP1, CD247, CD3G, LCK, JAK1, TLR2, PRKCQ, MAPK14 | More | | Torasemide | hsa05321 | Inflammatory bowel disease | 7.47E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | | Torasemide | hsa05332 | Graft-versus-host disease | 8.79E-03 | 3 | P01375, P26715, Q13241 | TNF, KLRC1, KLRD1 | More | | Torasemide | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | |